NCT02342379View on ClinicalTrials.gov

TH-302 in Combination With Bevacizumab for Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 4, 2019

Study Completion Date

December 4, 2019

Conditions
Glioblastoma
Interventions
DRUG

Bevacizumab

10mg/kg

DRUG

TH-302

670mg/m2

Trial Locations (2)

78229

University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02342379 - TH-302 in Combination With Bevacizumab for Glioblastoma | Biotech Hunter | Biotech Hunter